- Home
- KRMD vs GNLX Comparison
KRMD vs GNLX Comparison
Compare KRMD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- GNLX
- Stock Information
- Founded
- KRMD 1980
- GNLX 2001
- Country
- KRMD United States
- GNLX United States
- Employees
- KRMD N/A
- GNLX N/A
- Industry
- KRMD Medical/Dental Instruments
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- GNLX Health Care
- Exchange
- KRMD Nasdaq
- GNLX Nasdaq
- Market Cap
- KRMD 186.3M
- GNLX 202.4M
- IPO Year
- KRMD N/A
- GNLX 2023
- Fundamental
- Price
- KRMD $5.81
- GNLX $5.72
- Analyst Decision
- KRMD Strong Buy
- GNLX Strong Buy
- Analyst Count
- KRMD 3
- GNLX 4
- Target Price
- KRMD $4.83
- GNLX $19.75
- AVG Volume (30 Days)
- KRMD 173.0K
- GNLX 310.3K
- Earning Date
- KRMD 11-12-2025
- GNLX 11-05-2025
- Dividend Yield
- KRMD N/A
- GNLX N/A
- EPS Growth
- KRMD N/A
- GNLX N/A
- EPS
- KRMD N/A
- GNLX N/A
- Revenue
- KRMD $39,070,637.00
- GNLX N/A
- Revenue This Year
- KRMD $21.08
- GNLX N/A
- Revenue Next Year
- KRMD $16.37
- GNLX N/A
- P/E Ratio
- KRMD N/A
- GNLX N/A
- Revenue Growth
- KRMD 22.12
- GNLX N/A
- 52 Week Low
- KRMD $1.86
- GNLX $1.99
- 52 Week High
- KRMD $5.88
- GNLX $8.54
- Technical
- Relative Strength Index (RSI)
- KRMD 81.31
- GNLX 48.34
- Support Level
- KRMD $4.68
- GNLX $4.54
- Resistance Level
- KRMD $4.62
- GNLX $5.28
- Average True Range (ATR)
- KRMD 0.33
- GNLX 0.53
- MACD
- KRMD 0.16
- GNLX -0.11
- Stochastic Oscillator
- KRMD 93.15
- GNLX 59.88
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.